482TiP Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE
| Autor: | Mok, T., Schmid, P., de Castro, G., Syrigos, K., Martin, C., Yamamoto, N., Arén, O., Arrieta, O., Gottfried, M., Jazieh, A.R., Ramlau, R., Timcheva, C., Trani, L. |
|---|---|
| Zdroj: | In Annals of Oncology December 2016 27 Supplement 9:ix155-ix155 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|